GFM
TRVI icon

GF Fund Management’s Trevi Therapeutics TRVI Stock Holding History

GF Fund Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.7K Sell
2,717
-148
-5% -$2.15K ﹤0.01% 388
2026
Q1 		$34.2K Buy
2,865
+346
+14% +$3.87K ﹤0.01% 444
2025
Q4 		$31.5K Sell
2,519
-101
-4% -$1.17K ﹤0.01% 452
2025
Q3 		$24K Buy
2,620
+652
+33% +$4.89K ﹤0.01% 471
2025
Q2 		$10.8K Hold
1,968
– – ﹤0.01% 564
2025
Q1 		$12.4K Buy
1,968
+354
+22% +$1.69K ﹤0.01% 535
2024
Q4 		$6.65K Buy
+1,614
New +$5.17K ﹤0.01% 595

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

GF Fund Management's TRVI Position: Q2 2026 in Review

GF Fund Management reduced its Trevi Therapeutics (TRVI) stake by 5.2% in Q2 2026, selling an estimated $2.15K and leaving 2,717 shares worth $50.7K. The position accounts for ﹤0.01% of the portfolio, ranked #388.

GF Fund Management first reported a position in TRVI in Q4 2024 and has held it in 7 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • GF Fund Management held 2,717 shares of Trevi Therapeutics worth $50.7K as of Q2 2026.
  • GF Fund Management sold 148 Trevi Therapeutics shares in Q2 2026, an estimated $2.15K.
  • Trevi Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #388 holding.
  • GF Fund Management first reported a position in Trevi Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.